Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

INTRODUCTION: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Dermatol Ther (Heidelb)
Autores principales: Kuznik, Andreas, Bégo-Le-Bagousse, Gaëlle, Eckert, Laurent, Gadkari, Abhijit, Simpson, Eric, Graham, Christopher N., Miles, LaStella, Mastey, Vera, Mahajan, Puneet, Sullivan, Sean D.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698200/
https://ncbi.nlm.nih.gov/pubmed/28933010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-017-0201-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares